AI and rare disease: with great power comes great responsibility!

Monday 4 March 2024
12:00 - 13:30 (GMT)

Artificial Intelligence (AI) is fast becoming a universal theme in healthcare’s (r)evolution, offering the potential to improve diagnoses and tailor treatments. These advantages can be particularly important in rare diseases. However, the use of AI in rare diseases raises several questions about data security, equity, diversity, and responsibility, which have yet to be fully answered.

Join our upcoming online session to delve into AI’s transformative role in the evolution of healthcare.

Following on from our marking of Rare Disease Day on Thursday 29 February 2024, join us online to continue the discussion with this bite-sized educational session. Led by innovators in this field, the session will provide an opportunity to equip and inform interested learners about the foundation for the challenges posed and how they might be applicable in pharmaceutical medicine now and in the future.

What you will learn

  • Responsible research in artificial intelligence
  • Learnings from a pilot program
  • The challenges ahead


Prof Elvira Perez-Vallejos
Responsible research in artificial intelligence

Laura MacDonald and Mark Goodyear (Carecircle Technology Ltd)

Rare Diseases Implementation Group Coordinator
Learnings from a pilot program

Dr Tony Lockett
Chair of the FPM Rare Disease Expert Group and Senior Lecturer, King’s College London
The challenges ahead

Booking Information

Joining instructions will be emailed to registered attendees periodically, with a final reminder email sent one hour (online events) prior to the event. Please don’t forget to check your junk folder!

Queries: If you are unable to complete your booking online or have any questions, please email 


This event will take place online on:

Monday 4 March 2024 12:00-13:30 (GMT)

Price options:

FPM Members £40

Non-Members £60

Reduced rate* £20

*Reduced rates are available for FPM members who fulfil one of the following criteria: PMST trainees, people from low and lower-middle income countries, unemployed, part-time employed (earning less than £15,000 per year), people on Parental Leave, people who are Out of Practice & Retired, those who work for a charity.

This event is now clsoed for bookings.

Booking closes on Monday 4 March 09:00 (UK time).
Please see our booking terms and conditions and our privacy policy

CPD Credits

You can find instructions and guidance regarding CPD eligibility here.

Approve for CPD


Meet the speakers

Prof Elvira Perez-Vallejos

Elvira, Professor of Mental Health and Technology at School of Medicine and School of Computer Science (50/50 appointment) at the University of Nottingham (UoN) Elvira’s research portfolio (>£80M) is highly interdisciplinary with funding from UKRI (AHRC EPSRC, MRC) and NIHR. She specialises in assessing the impact that technology has on the mental wellbeing of groups with protected characteristics (children, young people, older adults) applying co-design and participatory methods (e.g., Youth Juries). She is driving world-leading research on digital mental health including issues of data ethics and privacy, user and stakeholder engagement, co-production, and responsible innovation.

Laura MacDonald

Laura Macdonald is Co-founder of Carecircle, leading the team in Product Development and Partnerships. Having worked extensively in strategic development across the private, public and third sector, including a long stint at the Royal College of Physicians, Laura looks for the opportunities of greatest impact at the intersection of industry problems. Laura has had the privilege of living and working in five countries to date, including one LDC and Silicon Valley and is driven to support social equity. A seasoned NED, serving on the board of various health and education charities, she also formed a patient organisation with her parents to support sufferers and carers of those with traumatic brain injury following her brother’s own catastrophic car accident. Carecircle is the product of her and the team’s unique approach to addressing unmet patient need and tackling pervasive problems regarding data availability and the ethical use of big data. Carecircle has been assessed by the UK Government’s Life Sciences Division as a “genuine innovation” and is proudly working with the Rare Disease Implementation Group in Wales as well as numerous international bodies focused on the care and research of Rare Diseases.

Mark Goodyear

Mark Goodyear, CEO of Carecircle, is a seasoned management consultant, mediator, and expert witness with a rich background in information technology. Co-founder of Carecircle, a global health platform, he took the helm as CEO in July 2022. Goodyear has provided invaluable IT consulting services across the UK, specialized in dispute resolution within technology sectors, and supported technology due diligence and incident analysis. His career milestones include senior partnership at Accenture, where he was pivotal in technology and research from 1998 to 2001 and played a critical role in the London Stock Exchange outage analysis in 2000. Goodyear’s education includes an MA in Engineering from Queens’ College, Cambridge.

Secure your spot now

You may also be interested in:

DPM Training

DPM Training Programme 2024 | Book All Modules

Find out more

DPM Training

DPM Training Programme 2024 | Module 5: Drug Safety

Find out more

DPM Training

DPM Training Programme 2024 | Module 6: Communication, Value and Access

Find out more

DPM Training

DPM Training Programme 2024 | Module 7: MCQ Exam Revision Course

Find out more

DPM Training

DPM Training Programme 2024 | Module 8: SAQ Exam Revision Course

Find out more

Managing Medical Emergencies in Human Pharmacology

Find out more

The views, information, or opinions expressed during FPM events and training are those of the individuals involved and do not necessarily represent those of the Faculty of Pharmaceutical Medicine. We value inclusivity, equality and diversity, and work hard to promote these whenever possible in all of our activities. We welcome your comments and feedback: